dalfopristin

dalfopristin

 [dal-fo´pris-tin]
a semisynthetic antibacterial effective against a variety of gram-positive organisms. It is used in conjunction with quinupristin in the treatment of serious bacteremia caused by vancomycin-resistant Enterococcus faecium and complicated skin and skin structure infections caused by Streptococcus pyogenes or methicillin-sensitive Staphylococcus aureus; administered intravenously.

dalfopristin

/dal·fo·pris·tin/ (dal-fo´pris-tin) a semisynthetic antibacterial used in conjunction with quinupristin against various gram-positive organisms, including vancomycin-resistant Enterococcus faecium.

dalfopristin

[dalfo′pristin]
a semisynthetic antibacterial effective against a variety of gram-positive organisms. It is used in conjunction with quinupristin in the treatment of serious bacteremia caused by vancomycin-resistant Enterococcus faecium and complicated skin and skin structure infections caused by Streptococcus pyogenes or methicillin-sensitive Staphylococcus aureus; it is administered intravenously.

dalfopristin

See Synercid®.
References in periodicals archive ?
8) dalfopristin Antibiotic VSE (N = 20), n (%) Susceptible Intermediate Resistant Erythromycin 12 (60) 6 (30) 2 (10) Ampicillin 9 (45) 6 (30) 5 (25) Vancomycin 20 (100) -- -- Teicoplanin 20 (100) -- -- Tetracycline 10 (50) 2 (10) 8 (40) Doxycycline 16 (80) 1 (5) 3 (15) Ciprofloxacin 7 (35) 4 (20) 9 (45) Levofloxacin 11 (55) 2 (10) 7 (35) Nitrofurantoin 20 (100) -- -- Rifampicin 2 (10) 9 (45) 9 (45) Linezolid 20(100) -- -- Tigecyclin 20 (100) -- -- Quinupristin/ 8 (40) 5 (25) 7 (35) dalfopristin
Tn5406, a New Staphylococcal Transposon Conferring Resistance to Streptogramin A and Related Compounds Including Dalfopristin.
AMP--ampicillin, IMP--imipenem, VA--vancomycin, LZD--linezolid, QD--quinupristin/ dalfopristin, SXT--trimethoprim/sulfamethoxazole, TGC--tigecycline.
For patients who have recently suffered from infection with vancomycin resistant Enterococcus (VRE) or MRSA, prophylaxis with linzolid, or quinupristin / dalfopristin can be considered.
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/ dalfopristin versus cefazolin, oxacillin or vancomycin.
Vancomycin, linezolid, gentamicin, moxifloxacin, quinupristin/ dalfopristin, and rifampicin were 100% effective (susceptible).
Concentracion Inhibitoria Minima Cepas de SCN Quinopristin / dalfopristin ([micro]g/mL) Numero Porcentaje 0.
The dalfopristin component interferes with early phases of bacterial protein synthesis and quinipristin interferes with the late phase of protein synthesis.
Treatment of methicillin - resistant Staphylococcus aureus infections with quinupristin - dalfopristin in patients intolerant of or failing prior therapy.
5 mg/kg BID Vancomycin- dalfopristin resistant enterococci Linezolid 7.